Computed Tomography–Based Radiomics Signature for Predicting Segmental Chromosomal Aberrations at 1p36 and 11q23 in Pediatric Neuroblastoma
-
Published:2023-11-27
Issue:
Volume:
Page:
-
ISSN:1532-3145
-
Container-title:Journal of Computer Assisted Tomography
-
language:en
-
Short-container-title:J Comput Assist Tomogr
Author:
Wang Haoru,Yu Chunlin,Ding Hao,Zhang Li,Chen Xin,He Ling
Abstract
Objective
This study aimed to develop and assess the precision of a radiomics signature based on computed tomography imaging for predicting segmental chromosomal aberrations (SCAs) status at 1p36 and 11q23 in neuroblastoma.
Methods
Eighty-seven pediatric patients diagnosed with neuroblastoma and with confirmed genetic testing for SCAs status at 1p36 and 11q23 were enrolled and randomly stratified into a training set and a test set. Radiomics features were extracted from 3-phase computed tomography images and analyzed using various statistical methods. An optimal set of radiomics features was selected using a least absolute shrinkage and selection operator regression model to calculate the radiomics score for each patient. The radiomics signature was validated using receiver operating characteristic curves to obtain the area under the curve and 95% confidence interval (CI).
Results
Eight radiomics features were carefully selected and used to compute the radiomics score, which demonstrated a statistically significant distinction between the SCAs and non-SCAs groups in both sets. The radiomics signature achieved an area under the curve of 0.869 (95% CI, 0.788–0.943) and 0.883 (95% CI, 0.753–0.978) in the training and test sets, respectively. The accuracy of the radiomics signature was 0.817 and 0.778 in the training and test sets, respectively. The Hosmer-Lemeshow test confirmed that the radiomics signature was well calibrated.
Conclusions
Computed tomography–based radiomics signature has the potential to predict SCAs at 1p36 and 11q23 in neuroblastoma.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Radiology, Nuclear Medicine and imaging
Reference28 articles.
1. Tumoral heterogeneity in neuroblastoma;Biochim Biophys Acta Rev Cancer,2022
2. Spontaneous regression of neuroblastoma;Cell Tissue Res,2018
3. Neuroblastoma: an updated review on biology and treatment;Curr Drug Metab,2019
4. Neuroblastoma: molecular pathogenesis and therapy;Annu Rev Med,2015
5. Chromosome 1p and 11q deletions and outcome in neuroblastoma;N Engl J Med,2005